Comparing the current results to its competitors, Rapt Therapeutics Inc reported Revenue decrease in the 3 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 14.62 %, recorded in the same quarter.
Rapt Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 150.37 %
November 27, 2023
RAPT Therapeutics Advances Treatment for Atopic Dermatitis with Promising Phase 1a/1b Clinical Trial of Zelnecirnon SOUTH SAN FRANCISCO, Calif., Nov. 27, 2023 - RAPT Therapeutics, a renowned clinical-stage biopharmaceutical company specializing in immunology-based therapies for inflammatory diseases and oncology, has made significant strides in the field with the publication of the Phase 1a/1b clinical trial results of their potential breakthrough drug, Zelnecirnon (formerly RPT193). The trial, which aimed to assess the safety and efficacy of Zelnecirnon in the treatment of moderate-to-severe atopic dermatitis (AD), showcased promising outcomes that could revolutionize the management of this debilitating...
Zai Lab Limited operates as a biopharmaceutical company primarily in China. The company seeks to discover, develop, and commercialize innovative medicines to address unmet medical needs in the country. Zai Lab focuses on licensing and acquiring clinical stage or late-stage development drugs, and then progressing them through regulatory approval and commercial launch.
Oncotelic Therapeutics Inc is a biotechnology company that focuses on developing and commercializing novel therapeutics for the treatment of cancer. Their business model revolves around conducting research to develop innovative drugs and therapies, and subsequently bringing those products to market to generate revenue and improve patient outcomes in cancer treatment.
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Sources:
Rapt Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Rapt Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
